Utility of GnRH-agonists for fertility preservation in women with operable breast cancer: Is it protective?

被引：19

作者：

Bedoschi G. ^{[1
,2
]}

Turan V. ^{[1
,2
]}

Oktay K. ^{[1
,2
]}

机构：

[1] Laboratory of Molecular Reproduction and Fertility Preservation, Obstetrics and Gynecology, New York Medical College, Valhalla, NY

[2] Innovation Institute for Fertility Preservation, IVF, New York, NY 10028

来源：

Current Breast Cancer Reports | 2013年 / 5卷 / 4期

关键词：

Breast cancer; Chemotherapy; Clinical trials; Fertility preservation; GnRH agonist; Gonadal damage; Gonadal suppression;

D O I：

10.1007/s12609-013-0123-y

中图分类号：

学科分类号：

摘要：

Breast cancer is the most common type of malignancy in reproductive-age women. Breast cancer chemotherapy is associated with premature ovarian failure, infertility, and negative psychosocial effects related to these reproductive changes. As a result of this, fertility preservation becomes highly critical in this group of women. Besides the fertility preservation methods that utilize assisted reproductive technologies such as embryo, oocyte, and ovarian tissue cryopreservation, another suggested strategy for fertility preservation is suppression of ovarian ovulatory function by gonadotropin-releasing hormone agonist (GnRHa) administration before and during chemotherapy. However, both the efficacy and safety of GnRH agonists for prevention of ovarian damage are unproven and the preponderance of evidence indicates that this is an ineffective strategy. This review details the most recent information and studies on this controversial topic. © 2013 Springer Science+Business Media New York.

引用

页码：302 / 308

页数：6

共 42 条

[1]

Siegel R., Naishadham D., Jemal A., Cancer statistics, 2013, CA Cancer J Clin, 63, pp. 11-30, (2013)

[2]

Anders C.K., Johnson R., Litton J., Phillips M., Bleyer A., Breast cancer before age 40 years, Semin Oncol, 36, pp. 237-249, (2009)

[3]

Howard-Anderson J., Ganz P.A., Bower J.E., Stanton A.L., Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: A systematic review, J Natl Cancer Inst, 104, pp. 386-405, (2012)

[4]

Loren A.W., Mangu P.B., Beck L.N., Et al., Fertility preservation for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 31, pp. 2500-2510, (2013)

[5]

Fertility preservation and reproduction in cancer patients, Fertility and Sterility, 83, 6, pp. 1622-1628, (2005)

[6]

Oktem O., Oktay K., Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function, Cancer, 110, 10, pp. 2222-2229, (2007)

[7]

Kim S.S., Klemp J., Fabian C., Breast cancer and fertility preservation, Fertil Steril, 95, pp. 1535-1543, (2011)

[8]

Letourneau J.M., Ebbel E.E., Katz P.P., Et al., Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer, Cancer, 118, pp. 1933-1939, (2012)

[9]

Oktem O., Oktay K., A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve, Cancer Research, 67, 21, pp. 10159-10162, (2007)

[10]

Soleimani R., Heytens E., Darzynkiewicz Z., Oktay K., Mechanisms of chemotherapy-induced human ovarian aging: Double strand DNA breaks and microvascular compromise, Aging, 3, pp. 782-793, (2011)

← 1 2 3 4 5 →